Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$6.99 USD
+0.21 (3.10%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $6.99 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ZVRA 6.99 +0.21(3.10%)
Will ZVRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZVRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZVRA
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
ZVRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
Other News for ZVRA
Zevra Therapeutics reports Q2 results
Zevra Therapeutics (ZVRA) Receives a Buy from Roth MKM
Zevra Therapeutics: Q2 Earnings Snapshot
Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
Zevra Therapeutics Inc options imply 8.4% move in share price post-earnings